Biomea Fusion

BMEA · NASDAQ

$0.7356−$0.0999 (−11.96%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $0.8355

Latest news

NewsOct 14, 8:02 AM ETAvi Kapoor
State Street, Fastenal And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
NewsOct 14, 2:12 AM ETTanya Rawat
What’s Going On With Biomea Fusion (BMEA) Stock After Hours?
Press releaseOct 13, 4:08 PM ETGlobe Newswire
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
NewsOct 13, 2:59 AM ETTanya Rawat
Biomea Fusion Stock Climbs 7% After-Hours: What's Going On?
Press releaseOct 12, 4:30 PM ETGlobe Newswire
Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
NewsSep 23, 2:12 PM ETVandana Singh
Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data
NewsSep 23, 1:57 AM ETTanya Rawat
Biomea Fusion Shares Fall 19% After Hours: Here’s Why
Press releaseSep 22, 4:05 PM ETGlobe Newswire
Biomea Fusion Announces Proposed Public Offering of Securities
Press releaseSep 3, 8:00 AM ETGlobe Newswire
Biomea Fusion to Participate in Upcoming Investor Conferences
NewsAug 24, 4:05 PM ETHenry Khederian
Biomea Fusion Stock Surges on Phase II Diabetes Trial Enrollment Completion
NewsAug 24, 1:06 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
Press releaseAug 24, 7:00 AM ETGlobe Newswire
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
Press releaseAug 13, 7:00 AM ETGlobe Newswire
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
Press releaseAug 5, 4:05 PM ETGlobe Newswire
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
Press releaseJun 5, 7:32 PM ETGlobe Newswire
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association ("ADA") 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
Press releaseJun 3, 8:00 AM ETGlobe Newswire
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
Press releaseMay 12, 4:05 PM ETGlobe Newswire
Biomea Fusion to Participate at Upcoming Investor Conferences
Press releaseMay 11, 4:54 PM ETGlobe Newswire
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
Press releaseApr 27, 5:37 PM ETGlobe Newswire
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
Press releaseMar 31, 7:00 AM ETGlobe Newswire
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
NewsMar 20, 8:05 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
NewsMar 14, 11:51 AM ETNabaparna Bhattacharya
Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib
Press releaseMar 14, 4:30 AM ETGlobe Newswire
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
Press releaseFeb 19, 7:00 AM ETGlobe Newswire
Biomea Fusion to Participate at Upcoming Investor Conferences
Press releaseDec 17, 7:00 AM ETGlobe Newswire
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference
Press releaseNov 24, 7:00 AM ETGlobe Newswire
Biomea Fusion to Participate at Upcoming Investor Conferences
Press releaseNov 10, 7:00 AM ETGlobe Newswire
Biomea Fusion to Participate at Jefferies London Healthcare Conference
Press releaseOct 21, 7:05 PM ETGlobe Newswire
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
NewsOct 7, 12:29 PM ETAvi Kapoor
Nasdaq Tumbles 200 Points; Trilogy Metals Shares Spike Higher
NewsOct 7, 10:35 AM ETVandana Singh
Biomea Fusion Stock Plummets Following Public Offering, Diabetes Study
NewsOct 7, 10:20 AM ETAvi Kapoor
Dow Jumps Over 100 Points; McCormick Earnings Top Views
Press releaseOct 6, 4:03 PM ETGlobe Newswire
Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
NewsJun 18, 2:55 PM ETAvi Kapoor
Crude Oil Moves Higher; US Weekly Jobless Claims Decline
NewsJun 18, 1:06 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsJun 18, 6:30 AM ETRishabh Mishra
US Stocks Likely To Open Higher Despite Trump's 'Unconditional Surrender' Call: All Eyes On Powell As Experts Predict Inflation Will Limit Fed's Rate Cut Capacity
NewsJun 18, 6:14 AM ETAvi Kapoor
Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket
NewsJun 17, 5:06 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseJun 4, 8:45 AM ETGlobe Newswire
Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities
Press releaseMar 24, 8:30 AM ETGlobe Newswire
Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose
Press releaseJan 13, 9:00 AM ETGlobe Newswire
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
Press releaseJan 6, 7:00 AM ETGlobe Newswire
Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Press releaseDec 17, 8:10 AM ETGlobe Newswire
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
Press releaseDec 16, 6:15 PM ETGlobe Newswire
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)
NewsSep 27, 12:20 PM ETVandana Singh
FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

State Street, Fastenal And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

What’s Going On With Biomea Fusion (BMEA) Stock After Hours?

Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist

Biomea Fusion Stock Climbs 7% After-Hours: What's Going On?

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data

Biomea Fusion Shares Fall 19% After Hours: Here’s Why

Biomea Fusion Announces Proposed Public Offering of Securities

Biomea Fusion to Participate in Upcoming Investor Conferences

Biomea Fusion Stock Surges on Phase II Diabetes Trial Enrollment Completion

12 Health Care Stocks Moving In Monday's Intraday Session

Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association ("ADA") 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

Biomea Fusion to Participate at Upcoming Investor Conferences

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

12 Health Care Stocks Moving In Friday's Pre-Market Session

Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib

Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026

Biomea Fusion to Participate at Upcoming Investor Conferences

Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference

Biomea Fusion to Participate at Upcoming Investor Conferences

Biomea Fusion to Participate at Jefferies London Healthcare Conference

Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series

Nasdaq Tumbles 200 Points; Trilogy Metals Shares Spike Higher

Biomea Fusion Stock Plummets Following Public Offering, Diabetes Study

Dow Jumps Over 100 Points; McCormick Earnings Top Views

Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations

Crude Oil Moves Higher; US Weekly Jobless Claims Decline

12 Health Care Stocks Moving In Wednesday's Intraday Session

US Stocks Likely To Open Higher Despite Trump's 'Unconditional Surrender' Call: All Eyes On Powell As Experts Predict Inflation Will Limit Fed's Rate Cut Capacity

Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Tuesday's After-Market Session

Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

Biomea Fusion to Become a Diabetes & Obesity Medicines Company

Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate